Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug class
1.2.2. Type
1.2.3. Action mechanism
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug class outlook
2.2.2. Type outlook
2.2.3. Action mechanism outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Europe Antibiotics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Europe Antibiotics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Europe Antibiotics Market: Drug Class Estimates & Trend Analysis
4.1. Technology Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Europe Antibiotics Market, by Drug Class Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Cephalosporin
4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Penicillin
4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Fluoroquinolone
4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. Macrolides
4.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.5. Carbapenems
4.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.6. Aminoglycosides
4.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.7. Sulfonamides
4.4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.8. 7-ACA
4.4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.9. Others
4.4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Europe Antibiotics Market: Type Estimates & Trend Analysis
5.1. Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Europe Antibiotics Market, by Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Branded Antibiotics
5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
5.4.2. Generic Antibiotics
5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Europe Antibiotics Market: Action Mechanism Estimates & Trend Analysis
6.1. Action Mechanism Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Europe Antibiotics Market, by Action Mechanism Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Cell Wall Synthesis Inhibitors
6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD million)
6.4.2. Protein Synthesis Inhibitors
6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.3. DNA Synthesis Inhibitors
6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.4. RNA Synthesis Inhibitors
6.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.5. Mycolic Acid Inhibitors
6.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Europe Antibiotics Market: County Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. Europe
7.5.1. UK
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.2. Germany
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.3. France
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.4. Italy
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.5. Spain
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.6. Norway
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.7. Sweden
7.5.7.1. Key country dynamics
7.5.7.2. Regulatory framework/ reimbursement structure
7.5.7.3. Competitive scenario
7.5.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key country dynamics
7.5.8.2. Regulatory framework/ reimbursement structure
7.5.8.3. Competitive scenario
7.5.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.4. Company Profiles
8.4.1. AbbVie, Inc.
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Pfizer Inc.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Novartis AG
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Merck & Co., Inc.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Teva Pharmaceutical Industries Ltd.
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Lupin Pharmaceuticals, Inc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Viatris, Inc.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Melinta Therapeutics LLC
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Cipla, Inc.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Shionogi & Co., Ltd.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. KYORIN Pharmaceutical Co., Ltd.
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives
8.4.12. GSK Plc
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product benchmarking
8.4.12.4. Strategic initiatives
8.4.13. Nabriva Therapeutics PLC
8.4.13.1. Company overview
8.4.13.2. Financial performance
8.4.13.3. Product benchmarking
8.4.13.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 Europe antibiotics market, by region, 2018 - 2030 (USD Million)
Table 3 Europe antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 4 Europe antibiotics market, by type, 2018 - 2030 (USD Million)
Table 5 Europe antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 6 Germany antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 7 Germany antibiotics market, by type, 2018 - 2030 (USD Million)
Table 8 Germany antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 9 UK antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 10 UK antibiotics market, by type, 2018 - 2030 (USD Million)
Table 11 UK antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 12 France antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 13 France antibiotics market, by type, 2018 - 2030 (USD Million)
Table 14 France antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 15 Italy antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 16 Italy antibiotics market, by type, 2018 - 2030 (USD Million)
Table 17 Italy antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 18 Spain antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 19 Spain antibiotics market, by type, 2018 - 2030 (USD Million)
Table 20 Spain antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 21 Denmark antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 22 Denmark antibiotics market, by type, 2018 - 2030 (USD Million)
Table 23 Denmark antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 24 Sweden antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 25 Sweden antibiotics market, by type, 2018 - 2030 (USD Million)
Table 26 Sweden antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
Table 27 Norway antibiotics market, by drug class, 2018 - 2030 (USD Million)
Table 28 Norway antibiotics market, by type, 2018 - 2030 (USD Million)
Table 29 Norway antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Europe antibiotics market: market outlook
Fig. 9 Tumor ablation competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Europe antibiotics market driver impact
Fig. 14 Europe antibiotics market restraint impact
Fig. 15 Europe antibiotics market: Drug class movement analysis
Fig. 16 Europe antibiotics market: Drug class outlook and key takeaways
Fig. 17 Cephalosporin market estimates and forecast, 2018 - 2030
Fig. 18 Penicillin estimates and forecast, 2018 - 2030
Fig. 19 Fluoroquinolone market estimates and forecast, 2018 - 2030
Fig. 20 Macrolides ablation estimates and forecast, 2018 - 2030
Fig. 21 Carbapenems market estimates and forecast, 2018 - 2030
Fig. 22 Aminoglycosides market estimates and forecast, 2018 - 2030
Fig. 23 Sulfonamides market estimates and forecast, 2018 - 2030
Fig. 24 7-ACA market estimates and forecast, 2018 - 2030
Fig. 25 Others estimates and forecast, 2018 - 2030
Fig. 26 Europe antibiotics Market: Drug class movement Analysis
Fig. 27 Europe antibiotics market: Drug class outlook and key takeaways
Fig. 28 Cephalosporin market estimates and forecasts, 2018 - 2030
Fig. 29 Penicillin market estimates and forecasts,2018 - 2030
Fig. 30 Fluoroquinolone market estimates and forecasts, 2018 - 2030
Fig. 31 Macrolides market estimates and forecasts, 2018 - 2030
Fig. 32 Carbapenems market estimates and forecasts, 2018 - 2030
Fig. 33 Aminoglycosides market estimates and forecasts, 2018 - 2030
Fig. 34 Sulfonamides market estimates and forecasts, 2018 - 2030
Fig. 35 7-ACA market estimates and forecasts, 2018 - 2030
Fig. 36 Others market estimates and forecasts, 2018 - 2030
Fig. 37 Europe antibiotics market: Type movement analysis
Fig. 38 Europe antibiotics market: type outlook and key takeaways
Fig. 39 Branded antibiotics market estimates and forecasts, 2018 - 2030
Fig. 40 Generic antibiotics market estimates and forecasts, 2018 - 2030
Fig. 41 Europe antibiotics Market: Action mechanism movement Analysis
Fig. 42 Europe antibiotics market: Action mechanism outlook and key takeaways
Fig. 43 Cell wall synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 44 Protein synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 45 DNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 46 RNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 47 Mycolic acid inhibitors market estimates and forecasts, 2018 - 2030
Fig. 48 Others market estimates and forecasts, 2018 - 2030
Fig. 49 Europe antibiotics market: Regional movement analysis
Fig. 50 Europe antibiotics market: Regional outlook and key takeaways
Fig. 51 Europe antibiotics market share and leading players
Fig. 52 Europe market share and leading players
Fig. 53 Europe SWOT
Fig. 54 Europe
Fig. 55 Europe market estimates and forecasts, 2018 - 2030
Fig. 56 UK
Fig. 57 UK market estimates and forecasts, 2018 - 2030
Fig. 58 Germany
Fig. 59 Germany market estimates and forecasts, 2018 - 2030
Fig. 60 France
Fig. 61 France market estimates and forecasts, 2018 - 2030
Fig. 62 Italy
Fig. 63 Italy market estimates and forecasts, 2018 - 2030
Fig. 64 Spain
Fig. 65 Spain market estimates and forecasts, 2018 - 2030
Fig. 66 Denmark
Fig. 67 Denmark market estimates and forecasts, 2018 - 2030
Fig. 68 Sweden
Fig. 69 Sweden market estimates and forecasts, 2018 - 2030
Fig. 70 Norway
Fig. 71 Norway market estimates and forecasts, 2018 - 2030
